Bioo Scientific has announced the availability of the MaxDiscovery™ Homocysteine Enzymatic Assay Kit, which uses a novel enzymatic technology for spectrophotometric detection of total homocysteine levels in serum from rodents and other mammals. Hyperhomocysteinemia, or elevated levels of total homocysteine (tHcy) in the blood, is an independent risk factor for neural tube defects, vascular diseases and Alzheimer’s disease, and is often associated with diseases such as colon cancer, osteoporosis, and Down syndrome. tHcy is used as a marker for vitamin deficiency, cardiovascular diseases, type 2 diabetes, homocystinuria and other diseases.
The novel MaxDiscovery Homocysteine Enzymatic Assay Kit employs simplified endpoint analysis to offer high sensitivity and low detection limits. This flexible assay can be performed manually for low throughput analysis and automated for high throughput requirements. The MaxDiscovery Homocysteine Enzymatic Assay measures the co-substrate conversion product. In a series of enzyme-catalyzed reactions, NADH is oxidized to NAD+, the amount of which is proportional to the levels of total homocysteine.
The MaxDiscovery Homocysteine Enzymatic Assay Kit is the latest addition to Bioo Scientific’s extensive MaxDiscovery line of preclinical assay kits.